A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Tradipitant (Primary)
  • Indications Pruritus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 31 Oct 2017 Status changed from recruiting to completed.
    • 02 Oct 2017 Data from this trial will be presented at the 9th World Congress of Itch (2017), according to a Vanda Pharmaceuticals Inc. media release.
    • 13 Sep 2017 Primary endpoint has not been met. (Efficacy of tradipitant relative to placebo in reducing chronic pruritus as measured by the Visual Analogue Scale (VAS).), according to a Vanda Pharmaceuticals media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top